Insulet revenue and financials
$135.34Change from previous close: −0.21%Absolute change: −$0.28
In the fiscal year ended December 2025, Insulet reported revenue of $2.71B (+30.73% year over year). Net income was $247.1M, a net margin of 9.1%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +30.73%
- 2025 vs 2024
- Net income growth
- −40.93%
- 2025 vs 2024
- Net margin
- 9.1%
- 2024: 20.2%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 88.4 | 114 | 183 | 126 | 197 | 63.8 | 148 | 108 | 86.8 | 87.6 | 45.2 | 56.0 |
| Depreciation and amortization | 26.7 | 26.2 | 24.4 | 22.0 | 22.3 | 21.7 | 21.5 | 21.3 | 19.2 | 18.8 | 18.8 | 18.7 |
| Capital expenditure | -32.5 | -24.3 | -135 | -25.6 | -18.6 | -12.3 | -53.6 | -26.7 | -22.5 | -22.1 | -29.3 | -20.1 |
| Investing cash flow | -37.4 | -27.7 | -153 | -31.0 | -23.3 | -15.6 | -68.0 | -29.3 | -24.9 | -24.0 | -31.6 | -22.6 |
| Financing cash flow | 4.0 | -320 | -72.5 | -457 | -344 | 278 | -20.8 | -1.9 | 8.8 | -14.1 | 2.2 | -6.9 |
| Share repurchases | -0.5 | -316 | -0.8 | -31.7 | -31.8 | -21.2 | -0.6 | -0.9 | -1.1 | -5.0 | -0.1 | -0.2 |
| Debt issued | 0.0 | 0.0 | 0.5 | 13.3 | 36.2 | 456 | 12.9 | 145 | 17.9 | — | — | — |
| Debt repaid | -4.6 | -4.5 | -81.8 | -532 | -418 | -183 | -39.5 | -147 | -15.1 | -14.9 | -6.7 | -6.8 |
| Effect of exchange rates | -0.5 | -1.9 | 0.7 | -1.9 | 8.9 | 3.8 | -8.1 | 4.7 | -0.9 | -2.5 | 3.0 | -1.2 |
| Net change in cash | 54.5 | -236 | -41.3 | -364 | -162 | 330 | 50.8 | 81.6 | 69.8 | 47.0 | 18.8 | 25.3 |
| Free cash flow | 55.9 | 89.5 | 48.2 | 100 | 178 | 51.5 | 93.9 | 81.6 | 64.3 | 65.5 | 15.9 | 35.9 |
| Levered free cash flow | 53.0 | 66.6 | -28.5 | 146 | 69.3 | -31.9 | 32.0 | 43.3 | 40.8 | 44.6 | -31.4 | 11.6 |